Genetic Susceptibility to Severe Forms of COVID-19: What we learned in 2022

Le résumé fourni par la source

Host genetics of COVID-19 patients is constantly evolving and may play an important role in the management of hospitalized patients and the identification of new biomarkers. In 2022, numerous studies have been published examining genetic factors that may be associated with severe outcomes of COVID-19 disease, as well as different genetic biomarkers have been suggested for early diagnosis of severe SARS-CoV-2 infection. In this literature review, we provide relevant updated analyses, examining studies published in 2022 in the literature that correlate with what was published in previous years and that focused on host genetics in patients with severe or fatal forms of COVID-19, Studies using different genotyping and sequencing techniques for the identification of genetic polymorphisms with promising results on different genes of the Renin angiotensin system, Interferon system, ABO system, Apolipoprotein E, Dipeptidyl petptidase, Leucine Zipper Transcription Factor-Like Protein 1(LZTFL1) and HLA system in diverse populations.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.